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Summary: Several studies indicate the relevance of lipoprotein(a) (Lp(a)) in the genesis of premature coronary
artery disease. A simple method for determining the concentration of Lp(a) is therefore of great interest for assessing
the risk of coronary artery disease in patients. We compared a new latex-enhanced immunonephelometric assay
(Behringwerke AG, Marburg, Germany), using the Behring Nephelometer System 100, with an established immu-
noenzymometric assay (Immuno, Heidelberg, Germany). A total of 163 patients was studied. Intra- and inter-assay
coefficients of variation were between 2.2% and 7.1%, and between 3.4% and 8.6%, depending on the concentration
of Lp(a). The correlation between the studied assays was excellent (r = 0.93, y = 0.98x -1.57, Spearman rank,
Passing & Bablok). When values above 1000 mg/1 for Lp(a) were excluded, the correlation was even higher.
Increased light scattering with particle size, which hitherto has been a disadvantage of the nephelometric technique,
seems to be negligible using the improved latex-enhanced approach. In patients with triacylglycerol values above
4.5 mmol/1 (n = 19) there was no interference with the Behring system, i. e. the results of the nephelometric method
were not increasing, and they agreed with those of the immunoenzymometric assay. In conclusion, this new latex-
enhanced nephelometric immunoassay represents a rapid and precise method for the quantification of Lp(a).
Introduction
Several studies indicate the relevance of Lp(a) in the
genesis of premature coronary artery disease (1—3). A
serum concentration of Lp(a) above 300 mg/1 in patients
with coronary artery disease seems to be an important
risk factor, especially if LDL-cholesterol is also
increased (4). Lp(a) deposits are detectable in atherosler-
otic lesions (5). The biochemical composition of Lp(a)
is similar to that of the LDL particle, which contains
apolipoprotein B-100, attached to the glycoprotein apol-
ipoprotein(a). Apolipoprotein(a) has striking similarities
to plasminogen (6—11); it exists in at least 34 different
phenotypic forms (Μτ 300000 to 800000), which are
genetically determined (12-16). Lp(a) has been found
to interfere with the binding of plasminogen to immobi-
lized fibrin and to the plasminogen receptor (17). Lp(a)
is therefore of major interest in studying the complex
interactions between coagulation and fibrinolytic sys-
tems and dyslipoproteinaemia in relation to atherogene-
sis.
Several methods for the quantification of Lp(a) are com-
mercially available for clinical diagnostic tests (18—28).
However, several difficulties must be overcome in order
to determine the concentration of Lp(a) specifically.
Since apolipoprotein(a) has a high homology to plas-
minogen, it is important to use an antibody in the detec-
tion system, which has no cross-reactivity with plasmin-
ogen. The high molecular heterogeneity of Lp(a) re-
quires polyclonal antibodies for routine use, which re-
cognize all isoforms of Lp(a). The variable number of
kringle-4 type 2 repeats in Lp(a) necessitate an antibody
directed towards other than kringle-4 domains in Lp(a).
Further limitations in quantitating Lp(a) are the huge
size range of Lp(a) and its distribution in various density
fractions within the serum. In addition, no commonly
used standard is yet available for the determination of
Lp(a)(30,31).
Many of the Lp(a) kits reported so far are time- and
cost-consuming. Here, we report a new simple, reliable,
and fully automated method for the determination of
Lp(a), using latex-enhanced immunonephelometry. The
advantages and disadvantages of this system are dis-
cussed.
Materials and Methods
Fasting venous blood samples were collected for lip id analysis.
Concentrations of triacylglycerols are quantitated colorimetrically
by the glycerolphosphate-oxidase/peroxidase method, using a com-
mercial standardized test kit (Boehringer Mannheim, Mannheim,
Germany) (32). Serum was prepared from the blood samples. Se-
rum samples were stored at 4 °C, and all serum samples were ana-
lysed within 24 h.
Serum was obtained from 163 patients during a period of 2 weeks.
All patients came for routine lipid analysis, as inpatients or outpa-
tients, to the Department of Gastroenterology and Hepatology of
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the Medical University of Hannover. No patient was excluded from
the study.
Immunoenzymomet r i c assay
To compare and validate the nephelometric immunoassay, Lp(a)
was quantitated by an immunoenzymometric assay (IEMA, Im-
munozym, Immuno, Heidelberg, Germany). This method is com-
mercially available and is commonly used as a well established
assay for Lp(a) (33, 34). It is a one-step immunoassay using a
monovalent polyclonal antibody (from sheep) as conjugate,
which is directed against the Fab fragment of apolipoprotein(a),
and is labelled with peroxidase. The resulting absorbance (mea-
sured at 450 nm) of the colorimetric reaction is proportional
to the concentration of Lp(a). The conditions used were those
recommended by the manufacturer. Lp(a) concentrations were
calculated as total mass using a calibration curve obtained from
a commercially available Lp(a) standard (Immuno, Heidelberg,
Germany). All samples and the standards were measured in
duplicate. The lower detection limit for this assay is 10 mg/1,
which is defined by the manufacturer.
Latex nephelometric assay
The newly developed latex-enhanced nephelometric assay for the
quantisation of Lp(a) was performed on a Behring Nephelometer
100 (BNA) (Behringwerke AG, Marburg, Germany) (22, 24, 35-
40). This method is based on the latex-enhanced particle agglutina-
tion technology. The antibody is a rabbit polyclonal anti-human
Lp(a) antiserum, which is conjugated to latex (N Latex-Lp(a), Beh-
ringwerke AG, Marburg, Germany). The γ-globulin fraction was
isolated and purified by immunoadsorption to remove apolipoprot-
ein B and plasminogen and subsequent ion exchange chromatogra-
phy. This step is important in order to minimize the cross-reactivity
of this Lp(a) assay with apolipoprotein B and plasminogen. Latex
particles (polystyrol, diameter 240 nm) are conjugated with anti-
human-Lp(a) γ-globulin fraction (coupling by adsorption) to en-
hance the turbidity of the antigen-antibody complexes. The light
scattering of this complex is proportional to the concentration of
the antigen Lp(a) at 840 nm. Light scattering was measured at time
0 and 6 minutes for each sample. Differences between the mea-
sured values were calculated automatically. This approach excludes
non-specific light scattering. Each serum sample (30 μΐ) was di-
luted 1: 100. The first 40 samples were also evaluated at a dilution
of 1 :400. A lyophilized Lp(a) control and standard serum were
used for the quantitation (lot # SY 084101 and SY 084003, Beh-
ringwerke AG, Marburg, Germany). The reaction buffer consisted
of polyethylene glycol, sodium chloride (11.6 g/1) in 0.05 mol/1
phosphate buffer pH 7.0, and sodium azide (< 1 g/1). N-Diluens
is a phosphate-buffered saline, pH 7.5, containing sodium azide
(< 1 g/1). Samples were measured in duplicate. The lower detec-
tion limit of this assay was 30 mg/1.
Statistics
Non-parametric regression analysis was performed according to
Passing & Bablok (41). The correlation1 coefficients were deter-
mined by linear regression analysis (Spearman rank).
Results
The patients studied were referred to us for further eval-
uation for their hyperlipoproteinaemia. None of the or>
tained sera were icteric or haemolytic as determined vis-
ually and by the qualitative detection of lipoprotein X.
The calibration curve of the latex-enhanced nephelomet-
ric assay depicted in figure 1 shows a linear response.
Intra-assay coefficients of variation were determined by
quantitating 20 replicate samples using 8 different serum
samples from patients with Lp(a) concentrations ranging
from 36 to 623 mg/1 using the nephelometric approach
(tab. 1). The best correlation coefficients of variation
(CV) were obtained within the range 75 to 471 mg/1
(2.23—3.82%). This range represents the concentrations
of Lp(a), which are most commonly seen in patients.
In addition it is within the cutoff point (Lp(a) serum
concentration of 300 mg/1) for identifying patients with
increased risk for coronary artery disease. An additional
sample with no detectable Lp(a) also gave a zero re-
sponse in 20 runs of the nephelometric assay. The intra-
assay coefficient of variation seen in the IEMA was
2.93% using pooled serum with an Lp(a) concentration
of 273 mg/1 (n = 20). The inter-assay variation coeffi-
cients were determined using the same serum samples
on 12 consecutive days. Within the range of 71 to 455
mg/1 the variation coefficients were less than 5% (tab.
1). The inter-assay coefficients of variation using the
IEMA was 4.34% using pooled serum Lp(a) = 273
1 -ι
0.8 -
0.6 -
0.4 -
0.2 -
1 2 3 4
Concentration of lipoprotein(a) [mg/l]
Fig. 1 The standard of 200 mg/1 was diluted 1 :40, 1 : 80,
1 : 160, 1 : 320, and 1 : 640 for the calibration curve. An'internal
control was determined to confirm the calibration curve. Samples
were diluted to the shown range of the Calibration curve to deter-
mine the concentration of Lp(a).
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mg/1). Therefore, the latex-enhanced inununonephelo-
metric method shows a good precision, which is compa-
rable with that of the IEMA used for comparison.
Figure 2 represents the comparison of the Lp(a) quantifi-
cation using the Behring system with that using the
IEMA from Immuno. The mean Lp(a) concentration was
254 ± 357 mg/1 (median = 90 mg/1) using the latex-
enhanced nephelometric assay and 238 ± 330 mg/1 (me-
dian = 106 mg/1) using the IEMA. All the studied sam-
ples revealed a highly significant correlation with
r = 0.93 and y = 0.98x - 1.57. A particularly high cor-
Tab. 1 Precision of the latex-enhanced nephelometric lipopro-
tein(a) assay
Lipoprotein(a) (mg/1) CV (%)
Mean SD
Intra-assay
(n = 20)
Inter-assay
(n = 12)
35.6
74.6
306.6
340.9
419.2
449.3
470.5
622.7
37.5
71.3
298.3
326.7
402.0
441.3
455.3
631.7
2.5
2.7
10.6
7.6
15.3
12.2
18.0
28.1
3.1
3.5
11.0
11.0
15.7
17.8
19.7
32.8
7.08
3.63
3.44
2.23
3.66
2.72
3.82
4.51
8.57
4.92
3.69
3.36
3.91
4.03
4.32
5.19
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Fig. 2 Comparison of the results for the quantification of Lp(a)
using the IEMA (Immuno) versus the latex-enhanced immuno-
nephelometric technique (n = 163). The correlation coefficient is
r = 0.93 and the regression line equation is y = 0.98x - 1.57, de-
termined by Passing & Bablok and linear regression analysis
(Spearman rank). In the latter 0.98 reflects the slope and 1.57 they
y-intercept.
relation was found for values up to 1000 mg/1. To deter-
mine the influence of triacylglycerols in the latex-en-
hanced nephelometric assay, patients will triacylglycer-
ols above 4.5 mmol/1 (n = 19) were studied, and the
results are depicted in figure 3. Although hypertriglycer-
idaemia is known to increase the light scattering in
nephelometric assay, the latex-enhanced immunonephe-
lometric method showed no increase in values in com-
parison with the studied IEMA. The mean triacylglyc-
erol values in these patients were extremely elevated,
with values of 13.4 ± 14.5 mmol/1 (median = 6.3
mmol/1). Lp(a) determined in these patients were 195
±213 mg/1 (median =70 mg/1) using the latex-en-
hanced nephelometric assay versus 236 ± 286 mg/1
(median = 30 mg/1) using the IEMA. These data may
even reflect an underestimation of the concentration of
Lp(a) by the nephelometric assay, compared with the
immunoenzymometric approach in pronounced hyp-
ertriglyceridaemic patients. This might be explained by
the excessive hypertriglyceridaemia observed in our
studied subjects. Since we used a predilution of 1 : 100
to test this particle-enhanced method, we also compared
the quantification of Lp(a) with a predilution of 1 : 400
in 50 patients. As shown in figure 4, there is a very high
correlation between these two different sample predilu-
tions (r = 0.998, y = 1.07x - 3.72).
Discussion
Lp(a) shares structural similarities with LDL. It consists
of one molecule apolipoprotein B and one molecule
apolipoprotein(a) (42, 43). Apolipoprotein(a) is enriched
with carbohydrates and displays a high degree of vari-
able size polymorphism (13, 15, 16, 44). Apolipopro-
tein(a) consists of a serine-protease domain and a krin-
gle-containing domain. The kringle domain is composed
of eleven different kringle forms. One of these kringle
forms has a high homology to the kringle 5 of plasmino-
gen (6). All other kringles of apolipoprotein(a) share a
high homology with kringle 4 of plasminogen (6). Krin-
gles are structural motifs which are also found in other
proteases involved in blood coagulation and fibrinolysis
(6). In addition, depending on the different methods
used to isolate and characterize the Lp(a) particle, there
is growing evidence that the particle itself is hetero-
geneous (45-47). Thus, the heterogeneity of apolipo-
protein(a), the differing composition of the Lp(a) par-
ticle, and the homology with other proteins and lipopro-
teins result in many problems for establishing a precise
and reliable method for the quantitation of apolipopro-
tein(a) or Lp(a).
There are many reports on various methods for the mea-
surement of the concentration of Lp(a) in human serum
or plasma (48,49). Amongst the different immunochcm-
ical approaches, immunoenzymometric assays are well
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Fig. 3 The values of all patients with triacylglycerols above 4.5
mmol/1 are shown. These patients had excessive hypertriglyceri-
daemia (13.4 ± 14.5 mmol/1 (median = 6.3 mmol/1)). Lp(a) values
determined in these patients were 195 ±213 mg/l (median = 70
mg/l) using the latex-enhanced nephelometric method versus 236
± 286 mg/l (median = 30 mg/l) using the IEMA.
established and represent the most commonly used tech-
nique for the detection of Lp(a) (26, 33, 34, 50, 51).
Immunonephelometric and immunoturbidimetric assays
are used increasingly, since these techniques are auto-
matable, and therefore offer a high throughput and are
cost-saving. Other advantages of the immunonephelo-
metric and immunoturbidimetric assays are that they do
not require isotopes and they are easy to perform. Re-
cently, Borque et al. showed that automated turbidimetry
on the Hitachi 911 analyser, using particle-enhanced
technology, is improving the performance of immuno-
1000 H
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Lipoprotein(a) (Behring Nephelometer) [mg/l]
1:400 sample predilutioo
Fig. 4 Values of 50 samples determined by the latex-enhanced
nephelometric method using a I : 100 versus a 1 : 400 predilution.
The correlation coefficient is r = 0.998 and the regression line
equation is y = 1.07x - 3.72).
turbidimetric assays of Lp(a) (25). We used the same
approach to compare the commonly used IEMA from
Immuno and a latex-enhanced immunonephelometric
assay on the BNA 100. The standards for Lp(a) were
provided by each manufacturer. Both methods were easy
to perform. Our data show high linearity, especially be-
tween 30 and 1000 mg/l, and a high correlation, with
r = 0.93 and the regression line equation of y = 0.98x
— 1.57. The coefficients of the intra- and inter-assay
variations were very similar for both methods, with low
imprecision for each. When Lp(a) values were deter-
mined in patients with excessive hypertriglyceridaemia,
we found no increased values for Lp(a) using the latex
nephelometric assay. Actually, in patients with increased
triacylglycerol concentrations, the Lp(a) values pro-
duced by the latex-enhanced method possibly tended to
be low. In addition, we assume that the wide range of
Lp(a) determined in our patients also reflects the differ-
ences in Lp(a) particle size. These differences in size of
apolipoprotein(a) and Lp(a) may result in different light
scattering, which in turn, should result in false high val-
ues of Lp(a). Since both methods agreed well and
showed high linearity (at least up to 1000 mg/l, fig. 2)
for this wide range of Lp(a), we believe that the known
disadvantage of increased light-scattering due to large
particles when using nephelometric systems seems to be
neglegible in this latex-erihanced version. However, we
did not specifically set out to answer this question in the
present study.
There still remain many problems to be resolved for an
international standardized precise -Lp(a) or apolipopro-
tein(a) measurement. However, the IEMA from Immuno
and the new latex-enhanced nephelometric assay from
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Behring are precise, especially within the range of Lp(a)
used as the cutoff to differentiate an increased risk of
atherogenesis and thrombogenesis (300 mg/1). The par-
ticle-enhanced version of the immunonephelometric ap-
proach does improve the reliability of the quantification
of Lp(a), and is therefore a promising method for the
clinical routine. Further studies are required to establish
the new generation of latex-enhanced nephelometric
technology for the quantification of proteins.
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